Stratistics MRC에 따르면 세계의 오소바이오로직스 시장은 2025년에 72억 달러를 차지하고 예측 기간 동안 CAGR 6.5%를 나타내며 2032년에는 112억 달러에 이를 것으로 예상됩니다.
오소바이오로직스는 근골격계 질환의 치유와 수복을 촉진하기 위해 생물학적 재료나 물질을 사용하는 것입니다. 촉구, 염증을 억제하고 치유 과정을 촉진하여 부상과 퇴행성 질환을 치료하기 위해 종종 정형 생물학적 제제가 사용됩니다.이 접근법은 관절, 인대, 힘줄, 뼈에 손상을 입은 환자에게 수술을 대체하는보다 자연스러운 선택을 제공하고 결과의 개선과 회복 시간.
ISAPS Global Survey에 따르면 성형외과의 수술 건수는 2022년에 11.2% 증가했습니다.
낮은 침습 수술에 대한 수요 증가
시장에서의 낮은 침습 수술 수요 증가는 전통적인 수술과 비교하여 회복 시간 단축, 합병증 위험 감소, 수술 후 통증 완화가 가능하다는 것을 배경으로 하고 있습니다. 따라서 환자는 점점 더 이러한 절차를 선호하고 있습니다. 기술이 향상되고 인지도가 높아짐에 따라 PRP 및 줄기 세포 치료와 같은 낮은 침습성 성형 생물학적 치료의 채택은 계속 증가하고 정형외과 치료의 상황을 변화시킬 것으로 예상됩니다.
표준화 부족
시장에서 표준화의 부족은 일관성이 없는 치료 결과나 안전성의 우려 등 심각한 과제를 초래합니다. 이러한 불일치는 환자의 신뢰를 저해하고 보급의 방해가 됩니다. 또한, 표준화된 프로토콜이 없기 때문에 규제 당국의 감시가 복잡해져, 실증되어 있지 않은 치료나 안전하지 않은 치료가 시장에 나와, 환자에 해를 미칠 가능성이 높아집니다.
재생 의료에 대한 의식이 높아짐
재생 의료에 대한 의식 증가는 환자와 건강 관리 제공업체가 치유 및 조직 복구의 가능성을 인식하고 있기 때문에 시장에 큰 영향을 미치고 있습니다. 교육이나 연구가 진행됨에 따라, 보다 빨리 회복해, 보다 좋은 결과를 얻기 위해서, 이러한 혁신적인 치료를 요구하는 사람이 늘어나고 있습니다.
고액의 치료비
시장에 나가는 치료비는 고액이기 때문에 많은 환자, 특히 충분한 보험이 적용되지 않는 환자에게는 이러한 첨단 치료에 대한 액세스가 제한되어 있습니다. 한 치료는 경제적 부담이 크므로 유익한 것으로 보이는 치료를 전달하는 환자도 있습니다.
COVID-19의 유행은 공급망을 혼란시키고 선택적 치료를 지연시키고 환자의 치료에 대한 접근을 제한함으로써 시장에 큰 영향을 미쳤습니다. 발사와 같은 재생 치료에 대한 수요가 줄어들었고, 또한 경제적 제약과 감염 위험에 대한 우려로 환자는 치료를 늦추거나 보류했습니다.
예측 기간 동안 요추 융합 분야가 최대가 될 전망
요추 융합 부문은 허리 척추의 치유와 융합을 촉진하기 위해 뼈 이식과 줄기 세포와 같은 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예상됩니다. 합병증을 줄이고 환자의 결과를 개선하는 것을 목표로 합니다. 낮은 침습 기술이 보급됨에 따라 척추 수술에서 재생 치료 수요가 증가하고 환자에게 회복을위한 더 나은 선택을 제공할 것으로 기대됩니다.
예측 기간 동안 치과 클리닉 분야의 CAGR이 가장 높아질 전망
예측 기간 동안 치과 클리닉 분야가 가장 높은 성장률을 보일 것으로 예상됩니다. 증가함에 따라 더 많은 치과 전문가들이 진료에 오소 바이오 로직을 도입하여 보다 빨리 회복하고 더 나은 장기적인 결과를 얻기 위한 고도로 낮은 침습적인 옵션을 환자에게 제공하고 치과 부문 내 수요를 밀어 올리고 있습니다.
예측 기간 동안 아시아태평양은 건강 의식이 높아짐에 따라 최대 시장 점유율을 차지할 것으로 예상됩니다. 헬스케어 인프라의 성장과 저침습 치료에의 시프트가, 정형 생물학적 제제 수요를 견인하고 있습니다. 또, 규제 프레임워크의 개선이나 의료 연구·기술에 대한 투자 증가도 시장을 지지하고 있습니다.
예측 기간 동안 북미가 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 더 많은 환자와 의료 종사자가 치유를 촉진하고 기존 약물과 수술에 대한 의존도를 줄이는 등 정형 생물학적 요법의 이점을 알면서 이러한 치료에 대한 수요가 높아지고 있습니다.
According to Stratistics MRC, the Global Orthobiologics Market is accounted for $7.2 billion in 2025 and is expected to reach $11.2 billion by 2032 growing at a CAGR of 6.5% during the forecast period. Orthobiologics is the use of biological materials and substances to promote healing and repair in musculoskeletal conditions. These therapies include stem cells, platelet-rich plasma (PRP), growth factors, and extracellular matrix proteins, which are derived from the body or synthesized. Orthobiologics are often used in orthopedics to treat injuries or degenerative diseases by stimulating tissue regeneration, reducing inflammation, and accelerating healing processes. This approach offers a more natural alternative to surgery, with the potential for improved outcomes and reduced recovery times for patients with joint, ligament, tendon, or bone injuries.
According to the ISAPS Global Survey, the number of procedures performed by plastic surgeons increased by 11.2% in 2022. About 18.8 million non-surgical and 14.9 million surgical procedures were performed worldwide, continuing the trend of a 41.3% increase over the last four years.
Growing demand for minimally invasive procedures
The growing demand for minimally invasive procedures in the market is driven by their ability to offer faster recovery times, reduced risk of complications, and less post-operative pain compared to traditional surgeries. Patients increasingly prefer these procedures due to their effectiveness in treating musculoskeletal injuries with minimal disruption to surrounding tissues. As technologies improve and awareness rises, the adoption of minimally invasive Orthobiologic treatments like PRP and stem cell therapies is expected to continue growing, transforming the landscape of orthopedic care.
Lack of standardization
The lack of standardization in the market poses significant challenges, including inconsistent treatment outcomes and safety concerns. Without clear guidelines, the quality and efficacy of therapies like stem cell injections and platelet-rich plasma (PRP) can vary widely, leading to unpredictable results for patients. This inconsistency undermines patient trust and can hinder widespread adoption. Additionally, the absence of standardized protocols complicates regulatory oversight, increasing the risk of unproven or unsafe treatments entering the market and potentially harming patients.
Rising awareness of regenerative medicine
Rising awareness of regenerative medicine is significantly influencing the market, as patients and healthcare providers recognize its potential for healing and tissue repair. Regenerative treatments, such as stem cell therapy and platelet-rich plasma (PRP), offer promising alternatives to traditional surgeries, addressing musculoskeletal injuries and degenerative conditions. As education and research advance, more people are seeking out these innovative treatments for faster recovery and improved outcomes. This growing awareness is driving the increasing demand and expansion of regenerative medicine in orthobiologic applications.
High cost of treatments
The high cost of treatments in the market limits access to these advanced therapies for many patients, particularly those without adequate insurance coverage. Expensive procedures like stem cell therapy or platelet-rich plasma (PRP) injections can be financially burdensome, leading some individuals to forgo potentially beneficial treatments. This not only creates inequities in healthcare access but also slows the widespread adoption of Orthobiologics, as patients may opt for more affordable, conventional treatments, even if they may not offer the same regenerative benefits.
The COVID-19 pandemic significantly impacted the market by disrupting supply chains, delaying elective procedures, and limiting patient access to treatments. Many orthopedic clinics and hospitals paused non-emergency services, leading to a reduction in the demand for regenerative therapies like stem cell treatments and PRP injections. Additionally, financial constraints and concerns over infection risks led patients to delay or forgo treatments. However, the pandemic also accelerated interest in minimally invasive and non-surgical options, which may drive future growth in the market.
The lumbar fusion segment is expected to be the largest during the forecast period
The lumbar fusion segment is expected to account for the largest market share during the forecast period such as bone grafts or stem cells, to promote the healing and fusion of vertebrae in the lower back. By integrating orthobiologic therapies, lumbar fusion aims to enhance healing, reduce complications, and improve patient outcomes. As minimally invasive techniques gain traction, the demand for regenerative treatments in spinal surgery is expected to increase, offering better recovery options for patients.
The dental clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the dental clinics segment is predicted to witness the highest growth rate. These biologic therapies help accelerate tissue regeneration, reduce inflammation, and improve the overall success of dental surgeries. As awareness of regenerative medicine grows, more dental professionals are integrating Orthobiologics into their practice, providing patients with advanced, minimally invasive options for faster recovery and better long-term results, boosting the demand within the dental sector.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to increasing healthcare awareness. Countries like Japan, China, and India are seeing greater adoption of treatments such as stem cell therapy, platelet-rich plasma (PRP), and bone grafts. Growing healthcare infrastructure, along with a shift towards minimally invasive procedures, is driving demand for Orthobiologics. The market is also supported by improving regulatory frameworks and increasing investments in medical research and technology.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR. Technological advancements in regenerative medicine, including stem cell therapies, gene therapies, and platelet-rich plasma (PRP) treatments, have boosted the efficacy of orthobiologic treatments. These innovations have led to greater adoption among both patients and healthcare providers.Moreover, As more patients and healthcare professionals learn about the benefits of orthobiologic therapies, such as accelerated healing and reduced dependency on traditional drugs or surgeries, demand for these treatments has risen.
Key players in the market
Some of the key players in Orthobiologics Market include Bioventus LLC, Nuvasive, Inc., Anika Therapeutics, Inc., Alphatec Spine, Inc., Medtronic plc, Stryker Corporation, Globus Medical, Inc., Xtant Medical Holdings, Inc., Sanofi S.A., Orthofix Medical Inc., Bone Therapeutics SA, RTI Surgical, Inc. , Kuros Biosciences Ltd. , Smith & Nephew plc, Integra LifeSciences Holdings Corporation , Seaspine Holdings Corporation and Arthrex, Inc.
In March 2025, Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager (MCE) that has shown robust B-cell depletion in pre-clinical and early clinical studies. DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted phagocytosis..
In March 2024, Stryker announced a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.